Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBX-3400 in Resistant Solid Tumors
NCT04640246Phase 2Unknown
- Sponsor
- Taiga Biotechnologies, Inc.
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of TBX-3400 in solid tumor, sponsored by Taiga Biotechnologies, Inc.. Status: unknown.
02
Drugs
TBX-3400
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04640246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640246.